Orzeyful (oveporexton)
Takeda Pharmaceuticals USA (TAK)
ApprovedAug 5, 2026
Marketer take
The first orexin agonist for narcolepsy type 1, a new mechanism that sleep specialists will weigh against oxybates and wake-promoting agents, so expect mechanism-of-disease education.
- Sponsor company
- Takeda Pharmaceuticals USA (TAK)
- Indication
- To treat narcolepsy type 1
- Therapeutic area
- Neurology, Sleep
- Event
- FDA approval
- Date
- Aug 5, 2026
- Status
- Approved
- Source
- FDA page
- Last verified
- Nov 15, 2026
Dates and status come from the linked public source as of the last verified date. Spot an error or have an update?